Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
80 Guest Street, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Olivia Ventures, Inc. (to 6/8/2020)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.14 K % +61.4%
Debt-to-equity 5.25 % -43.5%
Return On Equity -28.7 % -7.78%
Return On Assets -27.2 % -11.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138 M shares +8.76%
Common Stock, Shares, Outstanding 138 M shares +8.87%
Entity Public Float 283 M USD +53.8%
Common Stock, Value, Issued 14 K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 137 M shares +8.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12.4 M USD +3.8%
Operating Income (Loss) -53.4 M USD -20.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.4 M USD -13.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -45.4 M USD -13.9%
Earnings Per Share, Basic -0.35 USD/shares +2.78%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.7 M USD -12.4%
Marketable Securities, Current 133 M USD -10.5%
Cash, Cash Equivalents, and Short-term Investments 175 M USD
Assets, Current 159 M USD -13.6%
Property, Plant and Equipment, Net 744 K USD -45.8%
Operating Lease, Right-of-Use Asset 1.47 M USD -45.3%
Other Assets, Noncurrent 320 K USD 0%
Assets 161 M USD -14.3%
Accounts Payable, Current 854 K USD -24.1%
Accrued Liabilities, Current 1.82 M USD -79.7%
Liabilities, Current 3.89 M USD -65.2%
Operating Lease, Liability, Noncurrent 189 K USD -87.6%
Liabilities 4.08 M USD -67.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -90 K USD +38.4%
Retained Earnings (Accumulated Deficit) -326 M USD -16.2%
Stockholders' Equity Attributable to Parent 157 M USD -10.4%
Liabilities and Equity 161 M USD -14.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.9 M USD -13.6%
Net Cash Provided by (Used in) Financing Activities 17.4 M USD +42420%
Net Cash Provided by (Used in) Investing Activities -4.1 M USD -196%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 138 M shares +8.76%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -554 K USD +93%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Gross 44.3 M USD +53.6%
Operating Lease, Liability 1.41 M USD -46.5%
Depreciation 200 K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.4 M USD -13.3%
Lessee, Operating Lease, Liability, to be Paid 1.46 M USD -48.1%
Property, Plant and Equipment, Gross 7.17 M USD +0.42%
Operating Lease, Liability, Current 1.22 M USD +9.09%
Lessee, Operating Lease, Liability, to be Paid, Year Two 543 K USD -60.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 543 K USD -60.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49 K USD -72.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 543 K USD -60.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.3 M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 485 K USD -40%
Share-based Payment Arrangement, Expense 6.86 M USD +36.5%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%